Entera Bio Ltd. Reports Q2 2026 Financial Results

What Happened
Entera Bio Ltd. announced its financial results and business updates for the three months ended June 30, 2026 by issuing a press release on August 7, 2026. The Company furnished the press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02) and included an Interactive XBRL cover page (Exhibit 104). The release was also disclosed under Regulation FD (Item 7.01).

Key Details

• Filing date: August 7, 2026 (Form 8-K).
• Reporting period: three months ended June 30, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Interactive XBRL cover page included as Exhibit 104; information also disclosed under Regulation FD.

Why It Matters
This Form 8-K provides Entera Bio’s latest quarterly financial results and business updates that investors use to assess near-term performance and company progress. Investors should review the furnished press release (Exhibit 99.1) and the Interactive XBRL data for specific figures (revenue, net loss or income, cash position, and any operational or clinical updates) to inform investment decisions.